Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab

Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab

Abstract Background Macular edema secondary to retinal vein occlusion (RVO) is an important cause of loss of vision. Intravitreal injections (IVI) of anti-vascular endothelial growth factor (VEGF) are the standard of care in this disease, as shown in numerous randomized controlled trials. The purpos...

Full description

Bibliographic Details
Main Authors: Raja Narayanan, Aditya Kelkar, Zahir Abbas, Neha Goel, Manoj Soman, Naveen Naik, Aditya Sudhalkar, Jaydeep Walinjkar, Utkarsh Shah, Nitin Maksane
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Ophthalmology
Subjects:
Retinal vein occlusion
Ranibizumab
Macular edema
Open label prospective study
Visual acuity
Online Access:https://doi.org/10.1186/s12886-020-01757-7

Internet

https://doi.org/10.1186/s12886-020-01757-7

Similar Items